- Home
- TNGX
as 09-16-2025 4:00pm EST
Tango Therapeutics Inc is a biotechnology company. It is dedicated to discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. It is engaged in the business of discovering and developing precision oncology therapies. It is currently developing two MTA-cooperative PRMT5 inhibitors; TNG462 for non-CNS cancers, including pancreatic and lung cancer, and TNG456, a next-generation, brain-penetrant PRMT5 inhibitor, for CNS cancers, including GBM. Its pipeline products are PRMT5 and CoREST.
| Founded: | 2014 | Country: | United States |
| Employees: | N/A | City: | BOSTON |
| Market Cap: | 723.2M | IPO Year: | N/A |
| Target Price: | $10.00 | AVG Volume (30 days): | 1.5M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 6 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.32 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.03 - $10.81 | Next Earning Date: | 11-05-2025 |
| Revenue: | $24,296,000 | Revenue Growth: | -42.84% |
| Revenue Growth (this year): | 20.42% | Revenue Growth (next year): | -65.45% |
Stock Insider Trading Activity of Tango Therapeutics Inc. (TNGX)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Third Rock Ventures IV, L.P. | TNGX | 10% Owner | Sep 8 '25 | Sell | $7.04 | 86,459 | $608,628.13 | 14,727,516 | |
| Third Rock Ventures IV, L.P. | TNGX | 10% Owner | Sep 5 '25 | Sell | $7.00 | 642,906 | $4,500,342.00 | 14,727,516 | |
| Third Rock Ventures IV, L.P. | TNGX | N/A | Aug 22 '25 | Sell | $7.00 | 302,194 | $2,115,358.00 | 14,727,516 | |
| Third Rock Ventures IV, L.P. | TNGX | N/A | Aug 19 '25 | Sell | $7.01 | 1,100,000 | $7,712,760.00 | 14,727,516 |
Latest Tango Therapeutics Inc. News
TNGX Breaking Stock News: Dive into TNGX Ticker-Specific Updates for Smart Investing
MT Newswires
3 months ago
Tango Therapeutics Says First Patient Dosed in Cancer Treatment Combination Trial
GlobeNewswire
3 months ago
Tango Therapeutics Announces First Patient Dosed in Phase 1/2 Trial of TNG462 plus Revolution Medicines’ Daraxonrasib or Zoldonrasib in Patients with RAS-Mutant MTAP-deleted Pancreatic or Lung Cancer
Zacks
3 months ago
Tango Therapeutics (TNGX) Moves 7.5% Higher: Will This Strength Last?
GlobeNewswire
4 months ago
Tango Therapeutics to Participate in the 46th Annual Goldman Sachs Global Healthcare Conference
GlobeNewswire
4 months ago
Tango Therapeutics Announces First Patient Dosed in TNG456 Phase 1/2 Trial in Patients With MTAP-deleted Glioblastomas and Other Solid Tumors
Simply Wall St.
4 months ago
Tango Therapeutics, Inc. (NASDAQ:TNGX) Just Reported Earnings, And Analysts Cut Their Target Price
Simply Wall St.
4 months ago
Tango Therapeutics First Quarter 2025 Earnings: Misses Expectations
GlobeNewswire
4 months ago
Tango Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Highlights
Compare TNGX vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "TNGX Tango Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.